Chimerix (NASDAQ:CMRX) Coverage Initiated at StockNews.com

StockNews.com started coverage on shares of Chimerix (NASDAQ:CMRX) in a report issued on Sunday. The brokerage set a “hold” rating on the biopharmaceutical company’s stock.

Other equities research analysts also recently issued research reports about the company. Jefferies Financial Group reiterated a “hold” rating and issued a $8.50 price objective (down previously from $10.00) on shares of Chimerix in a report on Wednesday, March 5th. HC Wainwright reiterated a “neutral” rating and set a $8.55 price target (down from $11.00) on shares of Chimerix in a research note on Wednesday, March 5th. Finally, Wedbush reissued a “neutral” rating and set a $8.55 price target (up previously from $7.00) on shares of Chimerix in a research report on Wednesday, March 5th.

Chimerix Stock Performance

NASDAQ CMRX opened at $8.50 on Friday. The stock has a fifty day simple moving average of $5.44 and a 200-day simple moving average of $2.91. The stock has a market cap of $764.46 million, a PE ratio of -9.04 and a beta of 0.32. Chimerix has a twelve month low of $0.75 and a twelve month high of $8.52.

Chimerix (NASDAQ:CMRX) last posted its earnings results on Friday, March 21st. The biopharmaceutical company reported ($0.25) EPS for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.01. The company had revenue of $0.06 million during the quarter, compared to analyst estimates of $0.31 million. Research analysts predict that Chimerix will post -0.99 EPS for the current year.

Insider Transactions at Chimerix

In related news, CEO Michael T. Andriole sold 7,370 shares of the business’s stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $4.52, for a total transaction of $33,312.40. Following the completion of the transaction, the chief executive officer now directly owns 609,603 shares of the company’s stock, valued at $2,755,405.56. The trade was a 1.19 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Over the last 90 days, insiders have sold 20,760 shares of company stock valued at $91,175. 13.10% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Chimerix

A number of hedge funds have recently bought and sold shares of the stock. Bender Robert & Associates acquired a new position in shares of Chimerix during the fourth quarter worth about $37,000. Susquehanna Fundamental Investments LLC purchased a new stake in shares of Chimerix during the 4th quarter worth approximately $59,000. Jane Street Group LLC acquired a new position in shares of Chimerix in the 4th quarter valued at $62,000. Diadema Partners LP purchased a new position in shares of Chimerix in the 4th quarter valued at $101,000. Finally, Squarepoint Ops LLC acquired a new stake in Chimerix during the 4th quarter worth $130,000. Institutional investors and hedge funds own 45.42% of the company’s stock.

Chimerix Company Profile

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.